

A multi-centre, phase II-III randomised clinical trial and observational study of defibrotide for the treatment of hepatic veno-occlusive disease after stem cell transplant

Submission date 12/09/2003	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 12/09/2003	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 22/04/2015	Condition category Digestive System	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Kim Orchard

Contact details

Haematology Department, MP 8
Southampton General Hospital
Tremona Road
Southampton
United Kingdom
SO16 6YD

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0231120099

Study information

Scientific Title

A multi-centre, phase II-III randomised clinical trial and observational study of defibrotide for the treatment of hepatic veno-occlusive disease after stem cell transplant

Study objectives

Test the efficacy of defibrotide in the survival of patients for whom a diagnosis of veno-occlusive disease (VOD) is formulated and documented according to well predefined criteria.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Hepatic veno-occlusive disease (VOD)

Interventions

Randomised phase II-III multi-centre study of defibrotide in hepatic veno-occlusive disease after stem cell transplant.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Defibrotide

Primary outcome measure

Survival at 7, 14, 30, 60 and 100 days after diagnosis.

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/02/2003

Completion date

01/02/2005

Eligibility

Key inclusion criteria

All patients with diagnosis of VOD after a stem cell transplant.

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/02/2003

Date of final enrolment

01/02/2005

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Southampton General Hospital
Southampton
United Kingdom
SO16 6YD

Sponsor information

Organisation

Department of Health (UK)

Sponsor details

Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type

Government

Website

<http://www.doh.gov.uk>

Funder(s)

Funder type

Government

Funder Name

Southampton University Hospitals NHS Trust (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration